Piper Sandler analyst David Amsellem reiterated a Buy rating on Amgen (AMGN – Research Report) today and set a price target of $329.00. The ...

Four biosimilars for Stelara have launched in the United States this year following legal settlements with the reference ...

Positive results from the Tezspire phase III WAYPOINT trial highlight rapid and sustained effect in chronic rhinosinusitis with nasal polyps: Cambridge, UK Tuesday, March 4, 2025, ...

Hyderabad is rapidly establishing itself as a major life sciences hub, rivaling Bengaluru, thanks to a robust state-supported ...

Proficio Capital Partners LLC massively increased its stake in Amgen, acquiring 470,808 shares in Q4. This move significantly ...

Unlock the Secrets of AI with Expert Insights from Two Industry Leaders LUTZ, FL, UNITED STATES, March 3, 2025 /EINPresswire / -- Xraised r ...

Clinical-stage BridgeBio Oncology Therapeutics, whose financial backers include Cormorant Asset Management, is going public ...

GSK, Amgen and AstraZeneca released positive data supporting their rival drugs in a condition called chronic rhinosinusitis ...

Already billed as a potential blockbuster, Amgen and AstraZeneca’s Tezspire has turned in strong clinical data in chronic ...

Amgen and AstraZeneca's Tezspire showed significant reductions in nasal polyp severity, congestion, and surgery need in CRSwNP patients in the Phase 3 WAYPOINT trial.

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Last Friday, the three most widely followed benchmark indexes closed a mixed week. The Nasdaq Composite and the S&P 500 ...